GlassScriptPhysician profile
Eugene J Kim
NPI 1174963672
$783.75
in general payments reported to CMS, 2019-2025
16 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $33.93 · 2022: $328 · 2023: $52.00 · 2024: $43.50 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $212.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $300.00 | 2022 | |
| Tepha INC | $124.02 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $91.19 | 2023-2025 | |
| Astellas Pharma US INC | $43.36 | 2025 | Veozah |
| Roche Diagnostics Corporation | $40.20 | 2019 | |
| Medtronic, INC. | $29.32 | 2024 | Truclear |
| Abbvie INC. | $27.77 | 2022 | |
| Amag Pharmaceuticals, INC. | $19.54 | 2019 | |
| Covidien LP | $17.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.20 | 2023 | Jardiance |
| Coopersurgical, INC. | $17.06 | 2025 | Paragard T 380a |
| Boston Scientific Corporation | $16.85 | 2019 | |
| Exeltis, USA INC. | $14.18 | 2024 | Slynd |
| Allergan, INC. | $12.99 | 2019 | |
| Avion Pharmaceuticals | $12.57 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.